

POEM - Patient Orientated Eczema Measure

Category

Healthcare Tools

PLEASE REGISTER & LOGIN TO THIS MICRA GATEWAY PLATFORM TO PLACE AN ORDER.

The Patient Oriented Eczema Measure (POEM) is a simple, validated self-report questionnaire used for monitoring atopic eczema severity. It records seven symptoms shown to be important to patients. It is widely used in paper and electronic form for assessing and tracking eczema activity, both in clinical trials and in normal clinical practice. POEM is recommended by the National Institute for Health and Care Excellence (NICE) for assessing the severity of atopic dermatitis in NHS practice and has been recommended by the international Harmonising Outcome Measures for Eczema ([HOME](#)) group as a core outcome measure for eczema trials and for routine clinical practice.

About using POEM

1. POEM is free to use for non-commercial use, including public healthcare (government-funded), non-commercial research and personal use (please visit <https://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx>). You do not need a license to use POEM for research use or to create a translation for research use. If you are using the POEM instrument for non-commercial uses (e.g academic studies or in your clinic, we request that you send us an email with details of how you plan to use the scale (cebd@nottingham.ac.uk). This helps us track impact.
2. Since September 2022, POEM for commercial use (e.g commercial clinical trials) has required a fee. It is downloadable for commercial use exclusively via this website. If you have a query regarding the nature of your usage, then please get in touch. Commercial use of POEM implies that you agree to the Terms and Conditions that will download alongside POEM through this website.
3. Further information about how POEM was developed, translations available (non-commercial uses only) and best practice for its use is available from the Centre for Evidence Based Dermatology (CEBD).
4. The English version of POEM is copyright of the University of Nottingham. The non-English translations listed on the POEM website have been shared with the CEBD with permission to list on the POEM website to make these available to the dermatology community. The University of Nottingham is not able to warrant and does not warrant that users have the permission of the translation copyright holders to use the listed translations for commercial purposes. This licence and the payment on the order screen covers the use of the English-language version of the Questionnaire only. If you require versions of the POEM questionnaire in different languages, you will be able to request permission to produce translations during the ordering process.
5. Poem is available commercially on a per patient basis i.e if a clinical trial has 50 enrolled patients, 50 'users' must be purchased, regardless of the number of data collection time points for each participant. When selecting the number of 'users' on the payment page, make this equal to the number of enrolled patients. If more patients enrol after initial purchase, please

Learn more



return and purchase the additional number of patients. If you are purchasing more than 1000 users, you will need to place multiple orders as the largest order is 1000 users.

7. For any scale related queries please contact cebd@nottingham.ac.uk. For queries regarding payment or licensing please contact brian.sze@nottingham.ac.uk.

Payment

Please complete the order through this website and note the order reference.

To request an invoice and pay by bank transfer

Please send a purchase order / details listed below to simon.holmes@nottingham.ac.uk :

- Order reference from this platform
- Contact person
- Email address for accounts payable department (not order placer's email)
- Telephone number for accounts payable department (not order placer's number)
- Invoicing Address
- Company registration number
- For non UK customers, your VAT registration number if applicable
- Price, number of users and total cost

An invoice will then be issued.

To pay by card

An invoice will still need to be generated - which can then be paid via the University of Nottingham online store.

(link will be provided on / with the invoice when generated)

[Test link](#)

References

1. Charman C, Venn A, Williams HC.(2004) , The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective., Arch Dermatol, 140, 1513-1519
2. Charman CR, Venn AJ, Ravenscroft JC, Williams HC.(2013) , Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods., Br J Dermatol., 169(6), 1326-1332
3. Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CA, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J, HOME initiative collaborators(2016) , POEM a core instrument to measure symptoms in clinical trials: a HOME statement., Br J Dermatol
4. E. Grinich, J. Schmitt, D. Küster, P.I. Spuls, H.C. Williams, J.R. Chalmers, K.S. Thomas, C. Apfelbacher, C.A.C. Prinsen, M. Furue, B. Stuart, B. Carter and E. Simpson.(2018) , Standardized Reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): A Recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative., 10.1111/bjd.16732
5. Schram ME, Spuls PI, Leeftang MM, Lindeboom R, Bos JD, Schmitt(2016) , The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference., Allergy
6. Schram ME, Spuls PI, Leeftang MM, Lindeboom R, Bos JD, Schmitt J(2012) , EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference., Allergy, 67(1), 99-106
7. Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS; CLOTHES trial team(2018) , How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted? A validation using varied methods., Br J Dermatol.
8. L. Howells, S. Gran, J. R. Chalmers, B. Stuart, M. Santer, L. Bradshaw, D. M. Gaunt, M. J. Ridd, L. A. Gerbens, P. I. Spuls, C. Huang, N. A. Francis, K. S. Thomas.(2021) , Do patient characteristics matter when calculating sample size for eczema clinical trials? L., Skin Health and Dis., e42